Fig. 3From: Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumorsSurvival curves combination dabrafenib/trametinib vs. Nivolumab. TafMek: dabrafenib/trametinib; Nivo: nivolumab; RFS: risk free survival; OS: overall survivalBack to article page